More from the Author

• Case | HBS Case Collection | June 2020

  Breakthroughs at Blueprint Medicines

  Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

  Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development engine. Blueprint’s drug development strategy was twofold—it focused on creating a single drug compound for multiple disease indications, while at the same time developing drugs to track a disease through its progression. The company’s goal was to become a fully integrated biopharmaceutical company that could move from drug discovery to development to marketing. But it was increasingly challenging to prioritize and manage programs, personnel and partnerships.

  Keywords: precision medicine; cancer; biotechnology; drug development; Strategy; Expansion; Science; Genetics; Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts;

  Citation:

  Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.  View Details

  CiteView DetailsEducatorsPurchase

  Related

• Article | Harvard Business Review Digital Articles | March 6, 2020

  How Medical Nonprofits Set Winning Strategy

  Kathy Giusti and Richard G. Hamermesh

  Citation:

  Giusti, Kathy, and Richard G. Hamermesh. "How Medical Nonprofits Set Winning Strategy." Harvard Business Review Digital Articles (March 6, 2020).  View Details

  CiteView DetailsFind at Harvard Read Now

  Related

• Article | Journal of Precision Medicine

  How Harvard Business School Is Advancing Precision Medicine

  Kathy Giusti and Richard G. Hamermesh

  Citation:

  Giusti, Kathy, and Richard G. Hamermesh. "How Harvard Business School Is Advancing Precision Medicine." Journal of Precision Medicine (March 2020).  View Details

  CiteView Details Read Now

  Related